TURBO UNLIMITED SHORT- OPTIONSSCHEIN OHNE STOPP-LOSS-LEVEL - GENMAB | Market Closed - Deutsche Boerse AG 03:46:48 2024-07-05 pm EDT | ||
| 5.27 EUR | -2.23% |
|
| Current month | +0.19% | ||
| 1 month | +142.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GENMAB A/S
Latest news about GENMAB A/S
| Date | Price | Change |
|---|---|---|
| 24-07-05 | 5.27 | -2.23% |
| 24-07-04 | 5.39 | +2.08% |
| 24-07-03 | 5.28 | -6.05% |
| 24-07-02 | 5.62 | +2.55% |
| 24-07-01 | 5.48 | +4.18% |
Delayed Quote Deutsche Boerse AG
Last update July 05, 2024 at 03:46 pm EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GENMAB A/S |
| Issuer | 
Société Générale
|
| WKN | SW88XX |
| ISIN | DE000SW88XX0 |
| Date issued | 2024-04-19 |
| Strike | 2,131 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.95 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6 € |
|---|---|
| Lowest since issue | 1.14 € |
Company Profile
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Sector
-
Consensus: Genmab A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
1,755
DKK
Average target price
2,464
DKK
Spread / Average Target
+40.40%
- Stock Market
- Certificates
- Certificat
